Calgary, AB – TheNewswire - April 3, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has agreed to settle a portion, totalling 106,200,ofarrearsconsultingfeesowedtoitsCEO,NicholasKaros(the“Debt”). UIisinprocessofapplyingtotheTSXVentureExchange(the“TSXV”)toallowtheissuanceofupto4,248,000commonshares,ataminimumpriceof0.025 per share (or ...